Search

Your search keyword '"Laura Pala"' showing total 9 results
Start Over Author "Laura Pala" Publisher american association for cancer research (aacr)
9 results on '"Laura Pala"'

1. Figure S2 from Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion

Author

Giuseppe Giaccone, Aron Goldhirsch, Giuseppe Viale, Richard D. Gelber, Alberto Mantovani, Charles Swanton, Rachel Rosenthal, Jennifer Wargo, Paolo Veronesi, Hadine Joffe, Saverio Minucci, Emilio Bria, Giampaolo Tortora, Filippo De Marinis, Eleonora Nicoló, Paola Zagami, Gianmarco Orsolini, Maristella Saponara, Pier Francesco Ferrucci, Emilia Cocorocchio, Chiara Catania, Elisabetta Pennacchioli, Paola Queirolo, Tommaso De Pas, Vincenzo Bagnardi, Eleonora Pagan, Laura Pala, and Fabio Conforti

Abstract

Supplementary Figure S2

Published
2023

2. Table S2 from Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion

Author

Giuseppe Giaccone, Aron Goldhirsch, Giuseppe Viale, Richard D. Gelber, Alberto Mantovani, Charles Swanton, Rachel Rosenthal, Jennifer Wargo, Paolo Veronesi, Hadine Joffe, Saverio Minucci, Emilio Bria, Giampaolo Tortora, Filippo De Marinis, Eleonora Nicoló, Paola Zagami, Gianmarco Orsolini, Maristella Saponara, Pier Francesco Ferrucci, Emilia Cocorocchio, Chiara Catania, Elisabetta Pennacchioli, Paola Queirolo, Tommaso De Pas, Vincenzo Bagnardi, Eleonora Pagan, Laura Pala, and Fabio Conforti

Abstract

Supplementary Table S2

Published
2023

3. Figure S1 from Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion

Author

Giuseppe Giaccone, Aron Goldhirsch, Giuseppe Viale, Richard D. Gelber, Alberto Mantovani, Charles Swanton, Rachel Rosenthal, Jennifer Wargo, Paolo Veronesi, Hadine Joffe, Saverio Minucci, Emilio Bria, Giampaolo Tortora, Filippo De Marinis, Eleonora Nicoló, Paola Zagami, Gianmarco Orsolini, Maristella Saponara, Pier Francesco Ferrucci, Emilia Cocorocchio, Chiara Catania, Elisabetta Pennacchioli, Paola Queirolo, Tommaso De Pas, Vincenzo Bagnardi, Eleonora Pagan, Laura Pala, and Fabio Conforti

Abstract

Supplementary Figure S1

Published
2023

4. Legends of supplementary figure 1 and 2 from Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion

Author

Giuseppe Giaccone, Aron Goldhirsch, Giuseppe Viale, Richard D. Gelber, Alberto Mantovani, Charles Swanton, Rachel Rosenthal, Jennifer Wargo, Paolo Veronesi, Hadine Joffe, Saverio Minucci, Emilio Bria, Giampaolo Tortora, Filippo De Marinis, Eleonora Nicoló, Paola Zagami, Gianmarco Orsolini, Maristella Saponara, Pier Francesco Ferrucci, Emilia Cocorocchio, Chiara Catania, Elisabetta Pennacchioli, Paola Queirolo, Tommaso De Pas, Vincenzo Bagnardi, Eleonora Pagan, Laura Pala, and Fabio Conforti

Abstract

Legends of supplementary figure S1 and S2

Published
2023

5. Data from Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion

Author

Giuseppe Giaccone, Aron Goldhirsch, Giuseppe Viale, Richard D. Gelber, Alberto Mantovani, Charles Swanton, Rachel Rosenthal, Jennifer Wargo, Paolo Veronesi, Hadine Joffe, Saverio Minucci, Emilio Bria, Giampaolo Tortora, Filippo De Marinis, Eleonora Nicoló, Paola Zagami, Gianmarco Orsolini, Maristella Saponara, Pier Francesco Ferrucci, Emilia Cocorocchio, Chiara Catania, Elisabetta Pennacchioli, Paola Queirolo, Tommaso De Pas, Vincenzo Bagnardi, Eleonora Pagan, Laura Pala, and Fabio Conforti

Abstract

Purpose:We previously demonstrated that sex influences response to immune checkpoint inhibitors. In this article, we investigate sex-based differences in the molecular mechanisms of anticancer immune response and immune evasion in patients with NSCLC.Experimental Design:We analyzed (i) transcriptome data of 2,575 early-stage NSCLCs from seven different datasets; (ii) 327 tumor samples extensively characterized at the molecular level from the TRACERx lung study; (iii) two independent cohorts of 329 and 391 patients, respectively, with advanced NSCLC treated with anti–PD-1/anti–PD-L1 drugs.Results:As compared with men, the tumor microenvironment (TME) of women was significantly enriched for a number of innate and adaptive immune cell types, including specific T-cell subpopulations. NSCLCs of men and women exploited different mechanisms of immune evasion. The TME of females was characterized by significantly greater T-cell dysfunction status, higher expression of inhibitory immune checkpoint molecules, and higher abundance of immune-suppressive cells, including cancer-associated fibroblasts, MDSCs, and regulatory T cells. In contrast, the TME of males was significantly enriched for a T-cell–excluded phenotype. We reported data supporting impaired neoantigens presentation to immune system in tumors of men, as molecular mechanism explaining the findings observed. Finally, in line with our results, we showed significant sex-based differences in the association between TMB and outcome of patients with advanced NSCLC treated with anti–PD-1/PD-L1 drugs.Conclusions:We demonstrated meaningful sex-based differences of anticancer immune response and immune evasion mechanisms, that may be exploited to improve immunotherapy efficacy for both women and men.

Published
2023

6. Table S1 from Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion

Author

Giuseppe Giaccone, Aron Goldhirsch, Giuseppe Viale, Richard D. Gelber, Alberto Mantovani, Charles Swanton, Rachel Rosenthal, Jennifer Wargo, Paolo Veronesi, Hadine Joffe, Saverio Minucci, Emilio Bria, Giampaolo Tortora, Filippo De Marinis, Eleonora Nicoló, Paola Zagami, Gianmarco Orsolini, Maristella Saponara, Pier Francesco Ferrucci, Emilia Cocorocchio, Chiara Catania, Elisabetta Pennacchioli, Paola Queirolo, Tommaso De Pas, Vincenzo Bagnardi, Eleonora Pagan, Laura Pala, and Fabio Conforti

Abstract

Supplementary Table S1

Published
2023

7. Supplementary methods from Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion

Author

Giuseppe Giaccone, Aron Goldhirsch, Giuseppe Viale, Richard D. Gelber, Alberto Mantovani, Charles Swanton, Rachel Rosenthal, Jennifer Wargo, Paolo Veronesi, Hadine Joffe, Saverio Minucci, Emilio Bria, Giampaolo Tortora, Filippo De Marinis, Eleonora Nicoló, Paola Zagami, Gianmarco Orsolini, Maristella Saponara, Pier Francesco Ferrucci, Emilia Cocorocchio, Chiara Catania, Elisabetta Pennacchioli, Paola Queirolo, Tommaso De Pas, Vincenzo Bagnardi, Eleonora Pagan, Laura Pala, and Fabio Conforti

Abstract

Supplementary Methods

Published
2023

8. Table S3 from Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion

Author

Giuseppe Giaccone, Aron Goldhirsch, Giuseppe Viale, Richard D. Gelber, Alberto Mantovani, Charles Swanton, Rachel Rosenthal, Jennifer Wargo, Paolo Veronesi, Hadine Joffe, Saverio Minucci, Emilio Bria, Giampaolo Tortora, Filippo De Marinis, Eleonora Nicoló, Paola Zagami, Gianmarco Orsolini, Maristella Saponara, Pier Francesco Ferrucci, Emilia Cocorocchio, Chiara Catania, Elisabetta Pennacchioli, Paola Queirolo, Tommaso De Pas, Vincenzo Bagnardi, Eleonora Pagan, Laura Pala, and Fabio Conforti

Abstract

Supplementary Table S3

Published
2023

9. Abstract LB-115: Baseline neutrophil to lymphocyte ratio as a selection criterion for ipilimumab treatment in metastatic melanoma patients

Author

Gian Carlo Antonini Cappellini, Sara Gandini, Giovanni Amato, Diana Giannarelli, Emilia Cocorocchio, Angelo Battaglia, Chiara Martinoli, Salvatore Alfieri, Pier Francesco Ferrucci, Laura Pala, and Annamaria Di Giacomo

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Multivariate analysis, Proportional hazards model, business.industry, Cancer, Ipilimumab, medicine.disease, Surgery, Internal medicine, Cohort, medicine, Progression-free survival, Neutrophil to lymphocyte ratio, Selection criterion, business, medicine.drug
Abstract

Background: Ipilimumab, a recently approved immunomodulatory drug, improves the survival of metastatic melanoma patients. Despite documented, durable objective responses, a significant number of patients fails to obtain clinical benefit from treatment. The aim of this study was to identify a criterion to select patients best suited to receive this drug. Methods: Sixty-nine metastatic melanoma patients treated at the European Institute of Oncology with 3 mg/kg ipilimumab, were evaluated. Neutrophil to lymphocyte ratio (NLR) was calculated from pre-therapy full blood counts. Progression free survival (PFS) and overall survival (OS) were assessed using the Kaplan-Meier method, and multivariate Cox models were applied. Findings were independently validated on a cohort of 27 patients treated with 10 mg/kg ipilimumab at the University Hospital of Siena and on a cohort of 88 treated in Rome. Results: Best overall response and disease control rates were 9% and 27%, respectively. Median PFS and OS were 3 and 5 months, respectively. Pre-therapy NLR was identified as the strongest and independent marker for treatment benefit in univariate and multivariate analyses. Patients with baseline NLR Conclusions: Our findings show that baseline NLR is strongly and independently associated with outcome of patients treated with ipilimumab, and may serve as a selection criterion for this therapy. Citation Format: Pier Francesco Ferrucci, Sara Gandini, Angelo Battaglia, Salvatore Alfieri, Laura Pala, Annamaria Di Giacomo, Giovanni Amato, Gian Carlo Antonini Cappellini, Diana Giannarelli, Emilia Cocorocchio, Chiara Martinoli. Baseline neutrophil to lymphocyte ratio as a selection criterion for ipilimumab treatment in metastatic melanoma patients. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr LB-115. doi:10.1158/1538-7445.AM2015-LB-115

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results